No Data
CICC: Maintains HANSOH PHARMA "Outperform Industry" rating with a Target Price of HKD 21.12.
CICC released a research report stating that it maintains a "outperform the Industry" rating for HANSOH PHARMA (03692), being Bullish on the company's future progress in going global, and maintains a Target Price of HKD 21.12. Due to the possibility that the initial payment for this authorized cooperation may be confirmed in 2025, the bank has lowered its expectations for 2024 authorized revenue and maintained its expectations for 2025 authorized fees, thus reducing the 2024 profit forecast by 9.7% to 4.04 billion yuan while keeping the 2025 profit forecast unchanged. On December 18, 2024, the company announced the granting of a global exclusive license agreement for Merck's HS-10535 (oral GLP-1 receptor agonist). CICC
Chuangxin Biotechnology-B (02509.HK): Non-executive director Xue Mingyu resigns.
On December 10, Gelonghui reported that Chanson International Biological-B (02509.HK) announced that Non-Executive Director Xue Mingyu has resigned from his position as a Non-Executive Director and member of the Global Strategy Development Committee due to personal matters requiring more of his time, effective December 10, 2024. Xue Mingyu will serve as a consultant to the company.
Hong Kong stock movement | Zhenxin Biotechnology-B (02509) rose over 5% as the supplementary application for a new indication of Ustinumab injection was accepted by the NMPA.
Chun Shin Biotech Co., Ltd. - Class B (02509) rose more than 5%, as of the time of publication, it rose by 5.57%, closing at 11.38 Hong Kong dollars, with a turnover of 0.7366 million Hong Kong dollars.
Chongxin Biotech-B (02509.HK): The supplementary application of QX001S (Ustekinumab Injection) for children with plaque psoriasis has been accepted.
The announcement from Cansino Biologics-B (02509.HK) on December 2 revealed details about the QX001S framework agreement entered into with Hangzhou CMS East Pharmaceutical Co., Ltd. ("CMS East"), with the announcement published on September 12, 2024, regarding CMS East and the company's subsidiary Jiangsu Saifusheng Biotechnology Co., Ltd. ("Saifusheng") signing the "Wushinu Monoclonal Antibody Commissioned Production Agreement" Supplementary Agreement and setting the annual ceiling of the QX001S framework agreement, as well as the announcement published on November 5, 2024, concerning CMS East's receipt of national pharmaceutical products.
Express News | Qyuns Therapeutics Co Ltd - Subscription of Wealth Management Products
Retail Investors Invested in Qyuns Therapeutics Co., Ltd. (HKG:2509) Copped the Brunt of Last Week's HK$573m Market Cap Decline
No Data
